Niagen Bioscience(Nage) Financials: Return On Equity Compared To Industry Average, Plus Other Key Ratios
Profitability Trend (Last 5 Years)
Profitability - return on equity
This chart shows the historical trend of return on equity for NAGE compared to its industry average over the recent years.
Ratio Definition and Interpretation
Name: Return on Equity (ROE)
Definition: ROE shows how much profit the company earns for its shareholders based on their invested equity. It’s one of the most watched profitability ratios. A consistently high ROE signals strong management and efficient use of shareholder capital. But artificially high ROE may sometimes be boosted by excessive debt.
Interpretation:
• In '2021', NAGE's return on equity was -85.5%, measuring profitability for shareholders. Industry average for Medicinal Chemicals and Botanical Products in '2021' stood at 42.6%.
• In '2022', NAGE's return on equity was -54.8%, measuring profitability for shareholders. The increase since '2021' reflects strengthening financial performance. Industry average for Medicinal Chemicals and Botanical Products in '2022' stood at -50.5%. Industry average declined by 93.1% from previous year.
• In '2023', NAGE's return on equity was -17.3%, measuring profitability for shareholders. The increase since '2022' reflects strengthening financial performance. Industry average for Medicinal Chemicals and Botanical Products in '2023' stood at -64.8%. Industry average declined by 14.3% from previous year.
• In '2024', NAGE's return on equity was 22.9%, measuring profitability for shareholders. The increase since '2023' reflects strengthening financial performance. Industry average for Medicinal Chemicals and Botanical Products in '2024' stood at -23.0%. Industry average increased by 41.8% compared to previous year.
Overall, NAGE's return on equity has been volatile but showed an upward trend over the past 4 years.
Formula: ROE = Net Income / Shareholders' Equity
Good Range: 10%-20% desirable for many industries.